The small molecule anticancer therapy developer BlossomHill (BLSM.US) has set an IPO price of $15 to $17 per share, aiming to raise $125 million.

Biotech company BlossomHill Therapeutics, focused on developing small molecule cancer therapies and currently in the clinical preparation stage of Phase II, announced its initial public offering (IPO) terms on Monday. The company plans to issue 7.8 million shares at a price range of $15 to $17 per share, aiming to raise $125 million. The company intends to list on NASDAQ under the ticker symbol "BLSM." Founded in 2020 and based in San Diego, California, BlossomHill Therapeutics is dedicated to developing small molecule cancer drugs by identifying structural weaknesses in existing treatments and designing new compounds to overcome these weaknesses. The company's core candidate drug, BH-30643, targeting epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), is currently undergoing global Phase I/II clinical trials. The company plans to hold a Phase I clinical end-of-meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026 to discuss the recommended Phase II clinical dosing regimen and potential accelerated approval pathways for certain patients. The company also has two other candidate drugs: BH-30236, a CLK inhibitor currently undergoing Phase I clinical trials for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and BH-501284, a preclinical pan-KRAS project.